| abstract |
The present invention relates to new analogues of the neuropeptide Y, containing their pharmaceutical compositions containing their dosage forms, as well as to a method for treating diseases or conditions mediated by binding of the neuropeptide of the Y receptor. More specifically, the present invention relates to new analogs of the neuropeptide Y, including a proline substitution at position 34 and another substitution (s), as defined in the present invention, which selectively bind to the neuropeptide receptor of subtype Y1 compared to the neuropeptide receptor of subtype Y2. |